Please use this identifier to cite or link to this item:
10.3390/vaccines9080932
Title: | TBE vaccination breakthrough cases—Does age matter? |
Authors: | Schmitt, Heinz J. Dobler, Gerhard Zavadska, Dace Freimane, Zane Fousteris, Dimitrios Erber, Wilhelm Jodar, Luis Palmborg, Andreas Department of Paediatrics |
Keywords: | Older adults;Sweden;Tick-borne encephalitis;Vaccination failure;Vaccine failure;3.2 Clinical medicine;3.3 Health sciences;1.1. Scientific article indexed in Web of Science and/or Scopus database;Immunology;Pharmacology;Drug Discovery;Infectious Diseases;Pharmacology (medical);SDG 3 - Good Health and Well-being |
Issue Date: | 21-Aug-2021 |
Citation: | Schmitt , H J , Dobler , G , Zavadska , D , Freimane , Z , Fousteris , D , Erber , W , Jodar , L & Palmborg , A 2021 , ' TBE vaccination breakthrough cases—Does age matter? ' , Vaccines , vol. 9 , no. 8 , 932 . https://doi.org/10.3390/vaccines9080932 |
Abstract: | Tick-borne encephalitis (TBE) vaccines are highly effective in preventing TBE and vaccine failures (VF) are rare events. In this study, we compared the age distribution of TBE cases and TBE VF in three endemic countries: Sweden, Southern Germany, and Latvia. While the age distribution of TBE cases was similar for those <50 years versus those ≥50 years in all three countries, in Sweden, a higher proportion of VF cases was ≥50 years, whereas most VF cases in Latvia were <50 years of age and more evenly distributed between those <50 years versus those ≥50 in Southern Germany. Here, theoretical explanations were provided, including differences in diagnostic practices, vaccine uptake between age groups, behavioral patterns and underlying medical conditions, as to why VF were generally older in Sweden than the other countries. There is no scientific rationale to give an extra priming dose of TBE vaccine to subjects ≥50 years of age. |
Description: | Funding Information: Funding: This study was sponsored by Pfizer Inc. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. |
DOI: | 10.3390/vaccines9080932 |
ISSN: | 2076-393X |
Appears in Collections: | Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure |
Files in This Item:
File | Size | Format | |
---|---|---|---|
TBE_Vaccination_Breakthrough_Cases_Does_Age | 340.13 kB | Unknown | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.